Mon, March 3, 2025
Sun, March 2, 2025
Sat, March 1, 2025
Fri, February 28, 2025
Sun, February 23, 2025
Sat, February 22, 2025
Fri, February 21, 2025
[ Fri, Feb 21st ] - Wired
The Ozempic Shortage Is Over
Thu, February 20, 2025
Wed, February 19, 2025
Tue, February 18, 2025
[ Tue, Feb 18th ] - Politico
Culling the AI workforce
Mon, February 17, 2025
Sun, February 16, 2025
[ Sun, Feb 16th ] - LAist
Trump eyes NOAA
Sat, February 15, 2025

FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA


//science-technology.news-articles.net/content/2 .. ic-hypoparathyroidism-approved-in-australia.html
Published in Science and Technology on Thursday, February 20th 2025 at 12:22 GMT by manilatimes   Print publication without navigation

  • YORVIPATH
  • (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 First-in-class novel PTH replacement therapy Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH since FDA approval SINGAPORE,

The article from The Manila Times, published on February 21, 2025, discusses the approval of the first and only treatment for chronic hypoparathyroidism in Australia. This new treatment, named TRANSCON PTH (palopegteriparatide), has been developed by Ascendis Pharma A/S. Chronic hypoparathyroidism is a rare condition where the parathyroid glands do not produce enough parathyroid hormone, leading to low calcium levels in the blood. The approval by the Therapeutic Goods Administration (TGA) marks a significant advancement in managing this condition, offering patients a new therapeutic option to help normalize calcium levels and reduce the need for frequent calcium and vitamin D supplements. The treatment aims to improve the quality of life for those affected by providing a more physiological replacement of parathyroid hormone.

Read the Full manilatimes Article at:
[ https://www.manilatimes.net/2025/02/21/tmt-newswire/pr-newswire/first-and-only-treatment-for-chronic-hypoparathyroidism-approved-in-australia/2059832 ]

Publication Contributing Sources